Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts.
The new facility, which will include approximately 125,000 square feet of manufacturing, laboratory, and office space, will significantly increase the Company’s cell therapy manufacturing capacity to support the long-term growth of MACI® (autologous cultured chondrocytes on porcine collagen membrane) and Epicel® (cultured epidermal autografts). The Network Drive facility is expected to be completed in 2024, with commercial manufacturing expected to begin in 2025. The Network Drive Campus is designed and operated in accordance with existing LEED Gold and Fitwel Level 2 certifications and the new facility will be included in those certifications.
“We expect to sustain our strong long-term revenue growth for many years given our highly innovative products, significant barriers to entry and large underpenetrated markets,” said Nick Colangelo, President and Chief Executive Officer of Vericel. “This important manufacturing expansion plan represents another major milestone for the Company and demonstrates our confidence in the continued growth trajectory of MACI and Epicel in the years ahead. We also are very pleased to locate our new facility in a campus focused on developing and managing environmentally responsible real estate in the Boston area, which will ensure that we will have continued access to the world-class talent and infrastructure that is critical to our long-term success.”